HHHanafy Hafez

Hanafy Hafez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hanafy Hafez has a total of 98 co-authors. Here are the top co-authors by number of shared publications:

  • Alaa Elhaddad

    Pediatric Hematology/Oncology, National Cancer Institute, Cairo University, Cairo, Egypt

    3 shared publications
  • Alaa Elhaddad

    Pediatric Oncology Department, Children’s Cancer Hospital Egypt (CCHE-57357), Cairo 11311, Egypt

    3 shared publications
  • Leslie Lehmann

    Pediatric Oncology, Bone Marrow Transplant, Harvard Medical School, Boston Children's Hospital Dana‐Farber Cancer Institute Boston Massachusetts USA

    3 shared publications
  • Mahmoud Hammad

    Pediatric Hematology/Oncology, National Cancer Institute, Cairo University, Cairo, Egypt

    3 shared publications
  • Omneya Hassanain

    Biostatistics and Epidemiology Unit, Research Department, Children's Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt

    3 shared publications
  • Alaa El Haddad

    Department of Pediatric Oncology, Children’s Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt

    2 shared publications

Latest Publications

  • Risk of Depression and Anxiety Post Allogenic Hematopoietic Stem Cell Transplant in Pediatric Patients With Hematological Malignancies

    by Sally Boshra, Hanafy Hafez, Mahmoud Hammad, Taghreed Mohamed, Nayera Hamdy, Ahmed Mousa, Leslie Lehmann, Alaa El‐Haddad

    Background: Allogeneic Hematopoietic Stem Cell Transplant (allo‐HSCT) has improved survival among hematological malignancies. An increased prevalence of psychiatric conditions has been reported. However, psychosocial assessment is not consistently implemented across transplant follow‐up settings. Patients and Methods: This is a prospective study of pediatric patients who underwent allo‐HSCT at The Children's Cancer Hospital Egypt for hematologic malignancy from January 2018 to December 2021. Anxiety was assessed with the Spence Children's Anxiety Scale and Beck's Anxiety Inventory, while depression was assessed with the Child Depression Inventory and Beck's Depression Inventory. Based on the scores of these tests we grouped the patients into two categories: Absent/mild (A/M) and moderate/severe (M/S) for both depression and anxiety. Results: A total of 140 patients were included. The prevalence of M/S anxiety was 35% (27/77) and M/S depression 60% (39/65) in the whole cohort. 32% of patients had both M/S anxiety and depression. Younger age at transplantation was the only factor significantly associated with M/S anxiety (p value 0.037), with increasing likelihood of anxiety with younger age at HSCT. For depression, diagnosis was the only risk factor identified. Patients with acute myeloid leukemia (AML) had a higher prevalence of depression compared to those with other diagnoses. Conclusion: Anxiety and depression were common among pediatric allo‐HSCT survivors. These findings support incorporating routine psychological assessment into long‐term follow‐up, particularly for children transplanted at a younger age and those with AML.

  • Open Access

    Lessons learned from different prognostic factors analysis in intermediate-risk neuroblastoma: ten years’ experience at a tertiary center

    by Mustafa Selim, Hanafy Hafez, Abeer M. Elsayed, Mohamed Shalaby, Abdalwahab R. Abdalwahab, Soad A. Eltokhy, Mohamed Fawzy

    Background: Intermediate-risk (IR) neuroblastoma represents a biologically and clinically diverse group of tumors. This study evaluates the feasibility of surgical excision and identifies prognostic factors that influence survival in IR-neuroblastoma patients, particularly those with suboptimal responses to induction chemotherapy. Methods: We conducted a retrospective analysis of 50 pediatric patients diagnosed with IR-neuroblastoma at a tertiary cancer center between 2007 and 2016. Treatment responses, surgical outcomes, and survival data were assessed. Prognostic variables were evaluated using univariable and multivariable models. Results: After four cycles of induction chemotherapy, 26% of patients showed an objective response, increasing to 62% by treatment completion. Surgical resection was performed in 70% of patients, with a higher proportion among non-responders. Initial response to induction chemotherapy was a significant independent predictor of surgical feasibility ( p = 0.022) and final disease status ( p = 0.026). Five-year overall survival (OS) was 84%, and event-free survival (EFS) was 72%. Surgical resection significantly improved end-of-treatment disease status in slow-responder patients but did not independently affect OS or EFS. Conclusion: Moderate-intensity chemotherapy with or without surgery provides acceptable survival outcomes in IR-neuroblastoma. An early favorable response to induction therapy may justify avoiding surgery, while surgical resection remains critical for slow-responder patients.


  • Open Access

    Clinical and Molecular Characteristics of 100 Atypical Teratoid Rhabdoid Tumor Patients from Low- and Middle-Income Countries

    by Noha A. Ismail, Shaimaa Aboubakr, Amal Mosaab, Eslam Maher, Hanafy Hafez, Hala Taha, Dina Yassin, Amal Refaat, Mohamed S. Zaghloul, Mohamed El-Beltagy, et al.

    Background: Atypical teratoid rhabdoid tumor (ATRT) is a highly aggressive, rare pediatric central nervous system malignancy. Prognostic factors for optimizing risk stratification and management in a large uniformly treated cohort are lacking. Methods: We conducted a single-center retrospective cohort study analyzing clinical and outcome data for 100 newly diagnosed ATRT patients aged p = 0.047 and p = 0.002, respectively); however, only metastatic disease had a significantly negative effect on overall survival (OS) and cumulative incidence of relapse (CIR) (p = 0.002 for OS and p < 0.001 for CIR). DNA methylation was performed for 69 patients who were classified as having a TYR (n = 13), SHH (n = 34), MYC (n = 17), or non-ATRT diagnosis (n = 5). In the cohort of the 64 patients with ATRT defined by methylation, no significant survival differences were observed. Treatment-related deaths were reported in 28% of our studied group. Gram-negative septicemia was the most common cause of toxic death. The 5-year EFS and OS of the whole cohort were 12% and 13%, respectively. Conclusions: In this cohort, no significant survival differences were observed among the methylation subgroups. The higher treatment-related mortality in our cohort compared to the original protocol’s toxic-related deaths suggested that intensive and lengthy chemotherapy regimens may need modification for our population. The need for a short intensified approach, including a limited induction cycle followed by an intensified high-dose consolidation therapy, may be more appropriate for our patients with low socioeconomic status to avoid a repeated and prolonged course of protracted neutropenia.


  • Open Access

    Patterns of expression of VEGFR2, PDGFRs and c-Kit in pediatric patients with high grade non-rhabdomyosarcoma soft tissue sarcoma

    by Mona M. Mohammed, Hanafy A. Hafez, Enas M. Elnadi, Asmaa I. Salama, Abd Elaziz Saad Abd Elaziz, Gehad T. Ahmed, Madeeha A. Elwakeel, Mohamed K. Kamal, Mark W. Kieran, Alaa M. Elhaddad

    Introduction: Activated vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs) and c-Kit have been shown to be involved in the growth, invasion and metastasis of non-rhabdomyosarcoma soft tissue sarcoma tumor (NRSTS) with promising results for targeted therapy. Our aim was to assess the expression of these markers among different histological types and correlate with outcomes.Material and methods: This retrospective study included pediatric patients aged ≤ 18 years diagnosed with high-grade NRSTS who were treated at Children Cancer Hospital Egypt 57357 as per the COG NRSTS protocol (ARST0332). Expression of VEGFR2, PDGFRs (α and β) and c-Kit in tumor tissue was assessed by immunohistochemistry and correlated with clinical outcome.Results: Of 113 patients, 96 were eligible for the analysis with a median age of 11 years. Overall, 32.3% demonstrated high expression of PDGFRα, 17.7% for PDGFRβ, 19.8% for VEGFR2 and 8.3% exhibited positive expression for c-kit on the tumor cells. Most cases of synovial sarcoma (45.8%) and 43.7% of patients with undifferentiated sarcoma exhibited high expression of PDGFRα while 41.6% of MPNST showed high expression to PDGFRβ. The 5-year overall survival (OS), event free survival and relapse free survival (RFS) for the whole cohort were 59%, 54% and 60% respectively. In univariate analyses, only PDGFRα had a negative prognostic impact on relapse free survival (RFS) (p=0.03). In multivariate analyses, VEGFR2 was found to have a negative prognostic impact for OS (p = 0.02).Conclusion: Our findings indicated that tyrosine kinase receptors are upregulated in NRSTS and exhibited a distinct expression pattern within various subgroups. High expression of VEGFR2 and PDGFRα significantly correlated with reduced survival and may guide targeted therapy approaches for this poor prognosis group of patients.


  • Predictive value of micro-RNA expression profiling in pediatric desmoid fibromatosis

    by Mohamed Eid, Hanafy Hafez, Hend E. El-Shaqanqery, Omar Samir, Inas El Nadi, Madeeha Elwakeel, Asmaa Salama, Alaa Younes, Gehad Ahmed, Nouran Yasser, et al.

  • 179 Evidence-based medicine teaching in medical schools in the eastern mediterranean region (EMR)

    by Ranin Soliman, Reham Khedr, Hanafy Hafez, Manal Zamzam, Alaa Elhaddad, Carl Heneghan

    Objectives To determine current status of evidence-based medicine (EBM) teaching in medical schools in the Eastern Mediterranean Region (EMR), and make recommendations for improvements in EBM educational infrastructure in medical schools in the region. Method We developed a modified version of a published survey instrument to assess EBM teaching on the undergraduate and post-graduate levels in medical schools in the EMR. The adapted surveys will be piloted with several medical schools, revised, then sent by email to school deans, department chairs, or full-time faculty members to complete the surveys and provide outline of their EBM curriculum. To increase the response rate, follow-up emails will be sent to non-responders two weeks after the first email. We shall offer a second round of survey administration and/or personally contact the remaining non-respondents. Survey sections include the availability of taught EBM course(s), content and topics covered, format of teaching, persons involved in teaching, problems and future plans. The study was approved by the institutional Scientific Medical Advisory Committee (SMAC). Results The online surveys will be sent to medical schools in countries in the EMR region including; Egypt, Algeria, Bahrain, Iraq, Jordan, Kuwait, Lebanon, Morocco, Oman, Saudi Arabia, Tunisia, United Arab Emirates. Minimum response rate accepted is 30-40% of total number of medical schools included. Study results will be available for presentation at the conference. Conclusions Determining the current situation of EBM teaching in medical schools in the MENA region will help make recommendations to address any challenges in EBM teaching and inform the strategies of medical schools in the region regarding EBM training and teaching.

  • Open Access

    Providing care for pediatric cancer patients in the COVID‐19 era: Rapid response recommendations from a developing country

    by Mahmoud M. Elzembely, Yousra S. Abdelrahman, Shady Fadel, Hanafy Hafez


  • Outcomes of allogenic hematopoietic cell transplantation for childhood chronic myeloid leukemia: Single‐center experience

    by Hanafy A. Hafez, Amr Abdallah, Mahmoud Hammad, Nayera Hamdy, Dina Yassin, Sherine Salem, Omayma Hassanain, Lama Elhalaby, Alaa Elhaddad

    Background/objectives: Despite the apparent efficacy and favorable toxicity profile of TKIs, allogeneic SCT remains the only curative treatment for CML especially in younger patients, but TRM should be considered. We evaluated the clinical outcomes of pediatric CML patients who had SCT in our center.Methods: This retrospective study included children with CML, who received an allogeneic SCT at Children Cancer Hospital Egypt, 57357, from 2007 to 2017. All patients received myeloablative conditioning chemotherapy containing busulfan/cyclophosphamide followed by stem cell infusion from MRD.Results: From 121 patients diagnosed with CML, 43 had available MRD and subjected to HSCT while 78 patients continued TKI therapy. The median time to transplant from diagnosis was 13 months. At initial diagnosis, there were 39 patients in CP and 4 had blastic crises. Bone marrow harvest was the stem cell source in 32 patients, while 11 cases received mobilized peripheral blood stem cells with average stem cell dose of 4.45 × 106/kg. The probabilities of overall survival and event‐free survival at 5 years were 97.4% and 79.8%, respectively. TRM at 100 days and TRM at 1‐year post‐transplant were 0%. The incidence of chronic GVHD was significantly higher in peripheral blood than bone marrow stem cell source (P = .004).Conclusion: Considering the excellent survival rates and very low TRM, HSCT is still a valid option for pediatric patients with newly diagnosed CML with best using marrow stem cell source to avoid a significant risk of cGVHD and its related complications.


  • Incidence, risk factors, and outcome of blood stream infections during the first 100 days post‐pediatric allogeneic and autologous hematopoietic stem cell transplantations

    by Ahmed Youssef, Hanafy Hafez, Youssef Madney, Mervat Elanany, Omneya Hassanain, Leslie E. Lehmann, Alaa El Haddad

    Bloodstream infections (BSI) are a frequently observed complication after hematopoietic stem cell transplant (HSCT). Retrospective analysis of clinical and microbiological data during the first 100 days from 302 consecutive pediatric patients who underwent HSCT for a malignant disease at our institute between January 2013 and June 2017. A total of 164 patients underwent autologous and 138 allogeneic HSCT. The overall incidence of BSI was 37% with 92% of infectious episodes occurring during the pre‐engraftment phase. Gram‐positive bacteria (GPB) accounted for 54.6% of the isolated pathogens, gram‐negative bacteria (GNB) for 43.9%, and fungi for 1.4%. Coagulase‐negative staphylococci and Escherichia coli were the most commonly isolated GPB and GNB, respectively. Forty‐five percent of GNB were extended‐spectrum beta‐lactamase producers and 21% were multidrug‐resistant organisms. Fluoroquinolone resistance was 92% and 68%, among GPB and GNB, respectively. Risk factors for BSI in univariate analysis were allogeneic HSCT, delayed time to engraftment more than 12 days, previous BSI before HSCT, and alternative donor. In multivariate analysis, only HSCT type (allogeneic vs autologousP = .03) and previous BSI within 6 months before HSCT (P = .016) were significant. Overall survival at day 100 was 98% and did not differ significantly between patients with and without BSI (P = .76). BSI is common in children undergoing HSCT for malignant diseases. Allogeneic HSCT recipients and previous BSI within 6 months before HSCT are associated with increased risk of post‐transplant BSI. With current supportive measures, BSI does not seem to confer an increased risk for 100‐day mortality.


  • Outcome predictors of autologous hematopoietic stem cell transplantation in children with relapsed and refractory Hodgkin lymphoma: Single‐center experience in a lower‐middle‐income country

    by Amr Abdalla, Mahmoud Hammad, Hanafy Hafez, Mohamed Saad Zaghloul, Hala Taha, Gihan El‐Hennawy, Madeeha El‐Wakeel, Mohamed Khaled, Yasmin Mohamed, Alaa El‐Haddad

    Background: Children and adolescents with HL have excellent long‐term survival exceeding 95% after combined modality treatment. However, about 20% will either relapse or have PRF. Salvage HDCT followed by AHSCT is considered to be the preferential treatment.Objective: To describe the outcome (OS and EFS) and prognostic factors in pediatric patients with relapsed or refractory HL (r/rHL) who underwent AHSCT.Methods: We retrospectively included 43 pediatric patients with r/rHL who underwent AHSCT from July 1, 2007, till December 31, 2016, at the Children's Cancer Hospital of Egypt. MAC regimen given was CMV.Results: Of the whole cohort, 88.4% of patients achieved CR, while 11.6% had a positive PET scan prior to transplantation. The 3‐year OS and EFS were 85% and 70.6%, respectively. The 3‐year OS for patients > 10 years was 94% versus 65.5% for patients 10 years of age or younger (P = 0.046). There is strong tendency toward better 3‐year OS for patients with negative PET scan as compared to those with positive PET scan before AHSCT, 89.4% vs 60%, respectively (P = 0.059). This tendency is also applicable when looking at the 3‐year EFS for the two groups, 78.3% vs 40%, respectively (P = 0.069).Conclusion: Poor predictors of OS were younger age and positive PET scan before AHSCT. The latter, along with single modality treatment before AHSCT, were poor predictors of EFS.